ArticleFrontiers in human neuroscience2026
Vision In SyndrOmic Neurodevelopmental disorders-15q (VISiON-15q) study: eye tracking to supplement clinical examination for detection of cerebral/cortical visual impairment in children with Angelman and Duplication of 15q Syndromes.
Article in Frontiers in human neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Purpose: To identify children with Angelman syndrome (AS) and Duplication of 15q (Dup15q) syndrome who have cerebral/cortical visual impairment (CVI) using clinical examination combined with eye tracking. Design: Prospective cohort study. Participants: Twenty-five children (12 months to 12 years old) with AS and Dup15q syndrome, collectively termed 15q disorders. Methods: All participants underwent complete pediatric neuro-ophthalmologic evaluation, including assessment of visual acuity using the Visual Behavior Scale (VBS) and Teller acuity cards. The Higher Visual Function Question Inventory (HVFQI) was administered to assess parental report of behaviors suggestive of CVI. Eye tracking was performed in participants who were able to complete accurate calibration. Participants were also administered the Mullen Scales of Early Learning (MSEL) Visual Reception scale, as well as non-visual subscales. Parents completed the Vineland Adaptive Behavior Scales, 3 Main outcome measures: Proportion of participants classified as having diagnosis or high suspicion of CVI (15q-CVI-DHS) based on multimodal visual assessments; association between CVI status and MSEL, VABS-III, and CVFQ scores. Results: 15 of 25 (60%) of 15q participants were classified as 15q-CVI-DHS. Of these, 6 (40%) were classified based on eye tracking alone. Compared to children with low suspicion of CVI, children in the 15q-CVI-DHS group had lower MSEL visual reception (17.6 ± 12.4 vs. 43.9 ± 25.7, Discussion: Children with 15q disorders had a high rate of CVI or CVI suspect diagnosis, which was detected by eye tracking alone in 40% of cases. CVI was associated with worse vision-specific quality of life and lower developmental scores on multiple non-visual domains in these children. Future studies are needed to substantiate these findings in a larger cohort and characterize differences between genetic subtypes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.